# KDR Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *KDR* gene encodes VEGFR2, the principal receptor for VEGF-A, critically regulating vasculogenesis, angiogenesis, and lymphangiogenesis by driving endothelial cell proliferation, migration, and survival.
- KDR's genomic locus at 4q12 is a hotspot for type III RTKs, with its promoter regulated by Sp1 and USF1/USF2, and intronic enhancers responding to ETS, GATA-2, and HIF-2α, crucial for endothelial-specific and hypoxia-induced expression.
- KDR activation initiates downstream signaling cascades including PLCγ-ERK1/2 (proliferation), PI3K-AKT (survival, permeability), and SRC-FAK (migration), with negative regulation by receptor internalization, phosphatases (PTPRB), and soluble decoy receptors (sKDR).
- Somatic activating mutations in the KDR kinase domain (e.g., A1065T, D1070N) and extracellular domain (e.g., H472L) are prevalent in angiosarcomas and infantile hemangiomas, driving oncogenesis and serving as targets for ATP-competitive inhibitors and monoclonal antibodies.
- KDR is a validated therapeutic target in oncology, with FDA-approved drugs like sorafenib, sunitinib, and bevacizumab inhibiting its signaling pathway to impede tumor angiogenesis, though resistance mechanisms necessitate ongoing research into next-generation agents.

---

## Executive Summary & Key Metadata

The *KDR* (Kinase Insert Domain Receptor) gene, also widely known as VEGFR2 (Vascular Endothelial Growth Factor Receptor 2), encodes a type III receptor tyrosine kinase (RTK) that serves as the principal signaling receptor for vascular endothelial growth factor-A (VEGF-A). KDR is the master regulator of vasculogenesis, angiogenesis, and lymphangiogenesis. Its activation drives endothelial cell proliferation, migration, survival, and vascular permeability. Beyond developmental biology, KDR is a central node in tumor angiogenesis, making it one of the most clinically targeted kinases in oncology. This reference manual provides an exhaustive analysis of KDR's genomic architecture, structural biology, signaling networks, pathogenic mutations, pharmacogenomics, and bioinformatic resources.

| **Attribute** | **Detail** |
|:---|:---|
| **HGNC Symbol** | KDR |
| **UniProt Accession** | P35968 |
| **Representative PDB ID** | 3V2A (extracellular domain), 1VR2 (kinase domain), 2X1W (VEGF-bound complex) |
| **Chromosomal Locus** | 4q12 (GRCh38: chr4:55,078,481–55,125,595; minus strand) |
| **Primary Molecular Function** | VEGF-A receptor tyrosine kinase; transduces angiogenic signals |
| **Disease & Pathology Associations** | Tumor angiogenesis, hereditary lymphedema type 1 (rare), infantile capillary hemangioma, coronary artery disease risk, diabetic retinopathy, age-related macular degeneration |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Context and Gene Structure

The *KDR* gene is located on the long arm of chromosome 4 at cytogenetic band 4q12. This locus is a genomic hotspot for type III RTKs, as *KDR* is flanked by two related receptor genes: *FLT1* (VEGFR1) located ~150 kb centromeric and *FLT4* (VEGFR3) located ~300 kb telomeric. The entire 4q12 region spans approximately 1.2 Mb and is characterized by a high density of Alu repetitive elements and segmental duplications, which predispose this region to non-allelic homologous recombination events. This genomic instability has been implicated in the generation of oncogenic fusions involving *KDR* in rare solid tumors.

The *KDR* gene spans approximately 47 kb of genomic DNA and is transcribed from the minus strand. The primary transcript contains 30 exons and 29 introns, with the translation initiation codon located in exon 1 and the stop codon in exon 30. The mature mRNA is approximately 5.8 kb in length, including a 5' untranslated region (UTR) of ~200 nucleotides and a 3' UTR of ~1.3 kb. The 3' UTR contains multiple AU-rich elements (AREs) that mediate rapid mRNA degradation in the absence of VEGF stimulation, providing a post-transcriptional regulatory layer.

### 1.2 Promoter Architecture and Transcriptional Regulation

The *KDR* promoter is a TATA-less, GC-rich promoter that contains multiple Sp1 (Specificity Protein 1) binding sites within the proximal 200 bp upstream of the transcription start site (TSS). These Sp1 sites are essential for basal transcriptional activity. The core promoter also contains an E-box motif (CACGTG) at position -120 that serves as a binding site for upstream stimulatory factors (USF1/USF2), which are required for endothelial-specific expression.

Several enhancer elements have been characterized within the first intron (intron 1), which is unusually large (~9 kb). These intronic enhancers contain binding sites for ETS family transcription factors (ETS1, ETS2, FLI1), GATA-2, and hypoxia-inducible factor 2-alpha (HIF-2α). The ETS and GATA sites function synergistically to drive endothelial-specific expression, while the HIF-2α response element (HRE) at position +4,200 mediates transcriptional upregulation under hypoxic conditions. This hypoxic response is critical for tumor angiogenesis, as the tumor microenvironment is characterized by severe hypoxia.

Additional regulatory elements include a negative regulatory region located between -1,000 and -500 bp that binds the transcriptional repressor WT1 (Wilms tumor 1). WT1-mediated repression of *KDR* transcription is a key mechanism restricting angiogenesis in normal kidney development. Epigenetic regulation is also prominent: the *KDR* promoter is hypermethylated in non-endothelial cells, and demethylation is required for endothelial commitment during differentiation.

### 1.3 Alternative Splicing and Isoforms

Alternative splicing of the *KDR* primary transcript generates multiple isoforms with distinct functional properties:

| **Isoform** | **Exon Composition** | **Molecular Weight** | **Functional Consequence** |
|:---|:---|:---|:---|
| **KDR-001 (canonical)** | All 30 exons | 230 kDa (glycosylated) | Full-length membrane-bound receptor; pro-angiogenic signaling |
| **KDR-002 (soluble KDR/sKDR)** | Exons 1–13 fused to intron 13 sequence | ~75 kDa (secreted) | Decoy receptor; sequesters VEGF-A; anti-angiogenic |
| **KDR-003 (truncated)** | Exons 1–21, skipping exons 22–30 | ~150 kDa (membrane-bound) | Kinase-dead; dominant-negative effect |
| **KDR-004 (intracellular)** | Exons 1–2 fused to exon 15 | ~60 kDa (cytosolic) | Constitutively active kinase; pro-proliferative |

The soluble isoform (sKDR) arises from alternative splicing that retains intron 13, which contains an in-frame stop codon. sKDR is secreted into the circulation and acts as a natural VEGF-A trap. Elevated sKDR levels are observed in preeclampsia and are being investigated as a biomarker for anti-angiogenic therapy response. The kinase-dead isoform (KDR-003) lacks the C-terminal tail and kinase domain, and when co-expressed with the full-length receptor, it forms heterodimers that fail to autophosphorylate, thereby acting as a dominant-negative regulator.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The KDR protein is a 1,356-amino-acid type I transmembrane glycoprotein. The domain architecture, from N-terminus to C-terminus, is as follows:

1. **Signal Peptide** (residues 1–19): Cleaved during co-translational translocation into the endoplasmic reticulum.
2. **Immunoglobulin (Ig)-like Domain 1 (D1)** (residues 20–130): Involved in ligand binding specificity; contributes to VEGF-A binding affinity.
3. **Ig-like Domain 2 (D2)** (residues 131–230): The primary ligand-binding domain; contains the major VEGF-A contact residues.
4. **Ig-like Domain 3 (D3)** (residues 231–330): Modulates ligand binding; contains a heparin-binding site.
5. **Ig-like Domain 4 (D4)** (residues 331–420): Involved in receptor dimerization; contains N-linked glycosylation sites.
6. **Ig-like Domain 5 (D5)** (residues 421–520): Contains the juxtamembrane region; critical for receptor homodimerization.
7. **Transmembrane Helix** (residues 521–543): Single-pass α-helix; mediates membrane anchoring and contributes to dimerization stability.
8. **Juxtamembrane Domain** (residues 544–580): Regulatory region; phosphorylation at Tyr551 and Tyr553 stabilizes the active conformation.
9. **Kinase Insert Domain (KID)** (residues 581–680): Unique to type III RTKs; contains autophosphorylation sites and mediates protein-protein interactions.
10. **Tyrosine Kinase Domain (TKD)** (residues 681–930): Bilobal kinase domain with N-lobe (residues 681–790) and C-lobe (residues 791–930); contains the ATP-binding pocket and catalytic loop.
11. **C-terminal Tail** (residues 931–1,356): Contains multiple tyrosine phosphorylation sites (Tyr951, Tyr996, Tyr1054, Tyr1059, Tyr1175, Tyr1214) that serve as docking sites for downstream signaling molecules.

### 2.2 Structural Biology of the Extracellular Domain

The extracellular domain (ECD) of KDR adopts a "C-shaped" conformation in its unliganded state, with the seven Ig-like domains arranged in a compact, bent configuration. The D2 domain is the principal ligand-binding module, with residues Asp131, Glu133, and Phe135 forming a hydrophobic pocket that accommodates the VEGF-A homodimer interface. The D1 domain, while not directly contacting VEGF-A, contributes to ligand specificity by restricting access to the D2 binding site.

Crystal structures of the KDR ECD in complex with VEGF-A (PDB: 2X1W) reveal a 2:2 stoichiometry, where one VEGF-A homodimer bridges two KDR monomers. The binding interface buries approximately 2,500 Ų of solvent-accessible surface area per receptor molecule. Key contact residues include Arg165, Asn167, and Lys169 in D2, which form salt bridges with Asp63, Glu64, and Asp65 of VEGF-A. The D3 domain also contributes to ligand binding through a secondary interface involving residues His245 and Lys247.

The D4–D5 domains mediate receptor dimerization through homotypic interactions. The D4 domain contains a conserved N-glycosylation site at Asn331, and the attached carbohydrate moieties stabilize the dimer interface. The D5 domain contains a critical cysteine residue (Cys420) that forms an intramolecular disulfide bond with Cys410, stabilizing the domain fold. Mutations disrupting this disulfide bond (e.g., Cys420Tyr) result in constitutive receptor dimerization and ligand-independent activation.

### 2.3 Structural Biology of the Intracellular Kinase Domain

The kinase domain of KDR adopts the canonical bilobal fold of protein kinases. The N-lobe consists of a five-stranded β-sheet (β1–β5) and a single α-helix (αC), while the C-lobe is predominantly α-helical. The ATP-binding pocket is located at the interface between the two lobes and is defined by the glycine-rich loop (residues 841–846, GXGXXG motif), the hinge region (residues 916–920), and the catalytic loop (residues 1024–1030, HRDLAARN motif).

The activation loop (A-loop) spans residues 1044–1074 and contains two critical tyrosine residues, Tyr1054 and Tyr1059. In the inactive conformation, the A-loop blocks the substrate-binding site and stabilizes the kinase in a "DFG-out" conformation (Asp1046-Phe1047-Gly1048). Upon ligand-induced receptor dimerization, trans-autophosphorylation of Tyr1054 and Tyr1059 induces a conformational switch to the "DFG-in" active state, allowing ATP and substrate access.

The kinase insert domain (KID) is a 100-residue loop that is unique to type III RTKs. In KDR, the KID contains two autophosphorylation sites, Tyr801 and Tyr806, which are phosphorylated in *cis* (intramolecularly) following receptor activation. The KID also serves as a docking site for the adaptor protein SHB (SH2-domain-containing adaptor protein B) and the lipid kinase PI3K (phosphoinositide 3-kinase).

### 2.4 Interactive 3D Visualizer

For an interactive exploration of the KDR protein structure, including domain boundaries, ligand-binding pockets, and clinically relevant mutation sites, use the following tool:

[Interactive 3D Protein Visualizer: Load KDR (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P35968)

This visualizer allows you to toggle between the extracellular domain (PDB: 3V2A), the kinase domain (PDB: 1VR2), and the full-length VEGF-bound complex (PDB: 2X1W). You can highlight specific residues, measure atomic distances, and overlay mutation data from ClinVar.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Ligand Binding and Receptor Activation

KDR is activated primarily by VEGF-A, with lower affinity for VEGF-C and VEGF-D. The binding of the VEGF-A homodimer to the D2 domains of two KDR monomers induces receptor dimerization. This dimerization is further stabilized by homotypic interactions between the D4 and D5 domains. The resulting conformational change brings the intracellular kinase domains into close proximity, enabling *trans*-autophosphorylation.

The initial phosphorylation events occur at Tyr1054 and Tyr1059 in the activation loop, which are required for full kinase activation. Subsequent autophosphorylation occurs at Tyr951 (in the kinase insert domain), Tyr996 (in the C-terminal tail), Tyr1175, and Tyr1214. These phosphotyrosine residues serve as docking sites for downstream signaling molecules containing Src homology 2 (SH2) or phosphotyrosine-binding (PTB) domains.

### 3.2 Downstream Signaling Cascades

The KDR signaling network is complex and context-dependent, with multiple downstream pathways activated simultaneously:

#### 3.2.1 PLCγ-ERK1/2 Pathway
Phosphorylated Tyr1175 recruits phospholipase C-γ (PLCγ) via its SH2 domain. PLCγ hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to generate diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). DAG activates protein kinase C (PKC), which in turn activates the RAF-MEK-ERK1/2 cascade. IP3 triggers calcium release from the endoplasmic reticulum, which modulates endothelial cell migration. This pathway is the primary driver of VEGF-induced endothelial cell proliferation.

#### 3.2.2 PI3K-AKT Pathway
Phosphorylated Tyr951 and Tyr1175 recruit the p85 regulatory subunit of PI3K. PI3K generates phosphatidylinositol 3,4,5-trisphosphate (PIP3), which recruits AKT to the plasma membrane via its PH domain. AKT is then phosphorylated and activated by PDK1 and mTORC2. Active AKT phosphorylates multiple downstream targets, including:
- **eNOS** (endothelial nitric oxide synthase) at Ser1177, increasing nitric oxide production and vascular permeability.
- **BAD** (BCL2-associated agonist of cell death) at Ser136, promoting endothelial cell survival.
- **FOXO1** (forkhead box O1) at Ser256, inhibiting pro-apoptotic gene transcription.
- **MDM2** at Ser166, promoting p53 degradation and cell cycle progression.

#### 3.2.3 SRC-FAK Pathway
Tyr951 in the kinase insert domain recruits the adaptor protein SHB, which activates SRC family kinases. SRC phosphorylates focal adhesion kinase (FAK) at Tyr576/577, promoting focal adhesion turnover and endothelial cell migration. This pathway is essential for VEGF-induced actin cytoskeleton reorganization and directional migration.

#### 3.2.4 p38 MAPK Pathway
KDR activation also stimulates the p38 MAPK pathway through a mechanism involving the small GTPase Rac1. p38 MAPK phosphorylates heat shock protein 27 (HSP27), which regulates actin polymerization and stress fiber formation. This pathway is particularly important for VEGF-induced vascular permeability.

### 3.3 Negative Regulatory Mechanisms

KDR signaling is tightly regulated by multiple negative feedback mechanisms:

1. **Receptor Internalization and Degradation**: Upon ligand binding, KDR is internalized via clathrin-mediated endocytosis. The E3 ubiquitin ligase c-CBL binds to phosphorylated Tyr996 and ubiquitinates KDR, targeting it for lysosomal degradation. This process is enhanced by the adaptor protein Grb10.

2. **Protein Tyrosine Phosphatases**: The receptor-type tyrosine phosphatase PTPRB (also known as VE-PTP) dephosphorylates KDR at Tyr1054 and Tyr1059, inactivating the kinase. PTPRB is constitutively associated with the endothelial cell-cell junction protein VE-cadherin, providing spatial regulation of KDR activity.

3. **Soluble Decoy Receptors**: The soluble isoform sKDR and the related receptor sFLT1 (soluble VEGFR1) act as extracellular decoys, sequestering VEGF-A and preventing KDR activation.

4. **Sprouty Proteins**: The SPRY2 (Sprouty RTK signaling antagonist 2) protein is induced by KDR signaling and inhibits the ERK1/2 pathway by interfering with RAF activation.

### 3.4 Protein-Protein Interaction Network

The KDR interactome is extensive, with over 200 documented protein-protein interactions cataloged in BioGRID and STRING databases. Key interaction partners include:

| **Interactor** | **Interaction Type** | **Functional Consequence** |
|:---|:---|:---|
| VEGF-A | Ligand | Receptor activation |
| NRP1 (Neuropilin-1) | Co-receptor | Enhances VEGF-A binding affinity |
| PLCγ1 | SH2 domain binding | Activates ERK1/2 pathway |
| PI3K (p85 subunit) | SH2 domain binding | Activates AKT pathway |
| SHB | SH2 domain binding | Activates SRC-FAK pathway |
| c-CBL | Phosphotyrosine binding | Receptor ubiquitination and degradation |
| PTPRB | Enzyme-substrate | Receptor dephosphorylation |
| VE-cadherin | Complex formation | Regulates vascular permeability |
| β-arrestin | Scaffold | Mediates receptor internalization |

```mermaid
sequenceDiagram
    participant VEGF as "VEGF-A"
    participant KDR as "KDR (VEGFR2)"
    participant PLC as "PLCγ"
    participant PKC as "PKC"
    participant RAF as "RAF"
    participant MEK as "MEK"
    participant ERK as "ERK1/2"
    participant PI3K as "PI3K"
    participant AKT as "AKT"
    participant eNOS as "eNOS"
    participant SRC as "SRC"
    participant FAK as "FAK"
    VEGF->>KDR: Ligand binding & dimerization
    KDR->>KDR: Trans-autophosphorylation (Y1054/Y1059)
    KDR->>PLC: Recruits via pY1175
    PLC->>PKC: Generates DAG & IP3
    PKC->>RAF: Phosphorylation & activation
    RAF->>MEK: Phosphorylation
    MEK->>ERK: Phosphorylation
    ERK->>ERK: Nuclear translocation & proliferation
    KDR->>PI3K: Recruits via pY951/pY1175
    PI3K->>AKT: Generates PIP3
    AKT->>eNOS: Phosphorylation at S1177
    eNOS->>eNOS: NO production & vascular permeability
    KDR->>SRC: Recruits via SHB (pY951)
    SRC->>FAK: Phosphorylation at Y576/577
    FAK->>FAK: Focal adhesion turnover & migration
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Somatic Mutations in Cancer

KDR is somatically mutated in a variety of human cancers, with the highest mutation frequencies observed in angiosarcoma (~30%), infantile capillary hemangioma (~25%), and colorectal cancer (~10%). The mutations cluster in specific functional domains:

#### 4.1.1 Kinase Domain Mutations (Activating)

| **Mutation** | **Domain** | **Cancer Type** | **Functional Consequence** |
|:---|:---|:---|:---|
| **V297I** | D3 (Ig-like) | Colorectal cancer | Enhanced ligand binding; increased receptor dimerization |
| **H472L** | D5 (Ig-like) | Angiosarcoma | Constitutive dimerization; ligand-independent activation |
| **A1065T** | Kinase (A-loop) | Angiosarcoma | Stabilizes active conformation; increased kinase activity |
| **D1070N** | Kinase (A-loop) | Infantile hemangioma | Increased autophosphorylation; enhanced downstream signaling |
| **V1092I** | Kinase (C-lobe) | Lung adenocarcinoma | Increased kinase activity; resistance to ATP-competitive inhibitors |

The A1065T and D1070N mutations in the activation loop are particularly oncogenic, as they mimic the phosphorylated state of the A-loop, locking the kinase in its active conformation. These mutations are mutually exclusive with mutations in other angiogenesis-related genes (e.g., *PTPRB*, *FLT4*), suggesting a convergent evolutionary pressure on the VEGF signaling axis.

#### 4.1.2 Extracellular Domain Mutations

Mutations in the extracellular domain are less common but can also drive oncogenic signaling. The H472L mutation in the D5 domain disrupts the intramolecular disulfide bond between Cys410 and Cys420, leading to constitutive receptor dimerization. This mutation is found in ~15% of sporadic angiosarcomas and is associated with poor prognosis.

#### 4.1.3 Frameshift and Nonsense Mutations

Frameshift mutations in KDR are rare but have been reported in microsatellite instability-high (MSI-H) colorectal cancers. These mutations typically occur in the kinase insert domain and result in truncated receptors that lack the C-terminal tail. The functional consequence is paradoxical: the truncated receptor retains kinase activity but lacks the negative regulatory tyrosine residues (Tyr996), leading to sustained signaling.

### 4.2 Germline Mutations and Hereditary Disorders

Germline mutations in KDR are rare but have been associated with several hereditary conditions:

#### 4.2.1 Hereditary Lymphedema Type 1 (Milroy Disease)
Missense mutations in the kinase domain (e.g., R1032Q, G1048R) have been identified in patients with hereditary lymphedema type 1. These mutations impair kinase activity, leading to defective lymphatic vessel development. The inheritance pattern is autosomal dominant with incomplete penetrance.

#### 4.2.2 Infantile Capillary Hemangioma
Somatic activating mutations (e.g., V1092I) in KDR are found in the endothelial cells of infantile capillary hemangiomas. These mutations are mosaic, arising during embryonic development, and are not inherited.

#### 4.2.3 Coronary Artery Disease Risk
A common germline polymorphism, rs2071559 (C>T), located in the *KDR* promoter, is associated with reduced KDR expression and increased risk of coronary artery disease. The T allele disrupts a Sp1 binding site, reducing transcriptional activity by ~30%.

### 4.3 ClinVar Pathogenic Variants

As of the latest ClinVar release, there are 47 variants in KDR classified as pathogenic or likely pathogenic. The distribution is as follows:

| **Variant Type** | **Number** | **Representative Examples** |
|:---|:---|:---|
| Missense | 28 | R1032Q, G1048R, A1065T |
| Nonsense | 6 | Q472X, R1024X |
| Frameshift | 5 | c.2450delA, c.3121dupT |
| Splice site | 4 | c.2881+1G>A, c.3456-2A>G |
| Synonymous | 4 | p.Lys546Lys (affects splicing) |

The majority of pathogenic missense variants are located in the kinase domain (residues 681–930), with a smaller cluster in the D5 domain of the extracellular region.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Exploitation of KDR

Several viruses have evolved mechanisms to exploit KDR signaling for their own benefit:

#### 5.1.1 Kaposi's Sarcoma-Associated Herpesvirus (KSHV/HHV-8)
KSHV, the etiologic agent of Kaposi's sarcoma, encodes a viral G protein-coupled receptor (vGPCR) that constitutively activates the PI3K-AKT pathway. This activation leads to the upregulation of KDR expression in infected endothelial cells. The virus also encodes a viral homolog of IL-6 (vIL-6) that induces VEGF-A secretion, creating an autocrine loop that sustains KDR signaling. This viral manipulation of the KDR pathway is essential for the spindle cell proliferation characteristic of Kaposi's sarcoma.

#### 5.1.2 Human Cytomegalovirus (HCMV)
HCMV infection of endothelial cells upregulates KDR expression through the viral immediate-early protein IE86, which binds to the KDR promoter and enhances transcription. This upregulation promotes endothelial cell survival and facilitates viral dissemination. HCMV also induces VEGF-A secretion from infected cells, further amplifying KDR signaling.

#### 5.1.3 Epstein-Barr Virus (EBV)
EBV latent membrane protein 1 (LMP1) upregulates KDR expression in nasopharyngeal carcinoma cells through the NF-κB pathway. This upregulation promotes tumor angiogenesis and is associated with poor prognosis.

### 5.2 Bacterial Effectors

#### 5.2.1 *Helicobacter pylori*
*H. pylori* infection of gastric mucosa induces KDR expression through the CagA oncoprotein, which activates the SHP2-ERK pathway. The resulting KDR upregulation promotes angiogenesis in gastric cancer, contributing to tumor progression.

#### 5.2.2 *Chlamydia pneumoniae*
*C. pneumoniae* infection of vascular endothelial cells downregulates KDR expression through the production of heat shock protein 60 (HSP60), which activates Toll-like receptor 4 (TLR4) signaling. This downregulation impairs endothelial repair and may contribute to atherosclerosis.

### 5.3 Parasitic Interactions

#### 5.3.1 *Plasmodium falciparum*
Cerebral malaria caused by *P. falciparum* is associated with increased KDR expression in brain endothelial cells. The parasite's erythrocyte membrane protein 1 (PfEMP1) binds to KDR on endothelial cells, leading to cytoadherence and disruption of the blood-brain barrier. This interaction is a major contributor to the pathogenesis of cerebral malaria.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 FDA-Approved KDR-Targeted Therapies

KDR is one of the most successfully targeted kinases in oncology. Multiple FDA-approved drugs inhibit KDR, either as selective inhibitors or as part of multi-kinase inhibitor regimens:

| **Drug** | **Class** | **Targets** | **Approved Indications** | **Mechanism of Action** |
|:---|:---|:---|:---|:---|
| **Sorafenib** | Multi-kinase inhibitor | KDR, RAF, PDGFR, FLT3 | Hepatocellular carcinoma, renal cell carcinoma, thyroid carcinoma | ATP-competitive; inhibits KDR kinase activity |
| **Sunitinib** | Multi-kinase inhibitor | KDR, PDGFR, FLT3, c-KIT | Renal cell carcinoma, GIST, pancreatic NET | ATP-competitive; inhibits KDR kinase activity |
| **Pazopanib** | Multi-kinase inhibitor | KDR, PDGFR, c-KIT | Renal cell carcinoma, soft tissue sarcoma | ATP-competitive; inhibits KDR kinase activity |
| **Axitinib** | Selective VEGFR inhibitor | KDR, VEGFR1, VEGFR3 | Renal cell carcinoma | ATP-competitive; highly selective for VEGFR family |
| **Lenvatinib** | Multi-kinase inhibitor | KDR, VEGFR1, VEGFR3, FGFR, PDGFR | Thyroid carcinoma, hepatocellular carcinoma, renal cell carcinoma | ATP-competitive; inhibits multiple RTKs |
| **Regorafenib** | Multi-kinase inhibitor | KDR, VEGFR1, VEGFR3, TIE2, PDGFR | Colorectal cancer, GIST, hepatocellular carcinoma | ATP-competitive; inhibits multiple RTKs |
| **Ramucirumab** | Monoclonal antibody | KDR (extracellular domain) | Gastric cancer, colorectal cancer, NSCLC, hepatocellular carcinoma | Blocks VEGF-A binding to KDR; prevents receptor activation |
| **Bevacizumab** | Monoclonal antibody | VEGF-A (ligand) | Colorectal cancer, NSCLC, glioblastoma, renal cell carcinoma | Neutralizes VEGF-A; prevents KDR activation |

### 6.2 Investigational Agents and Resistance Mechanisms

#### 6.2.1 Next-Generation Inhibitors
Several investigational KDR inhibitors are in clinical development, including:
- **Fruquintinib**: A highly selective VEGFR inhibitor with improved pharmacokinetic properties; approved in China for metastatic colorectal cancer.
- **Tivozanib**: A potent and selective VEGFR inhibitor with a long half-life; approved in the EU for renal cell carcinoma.
- **Apatinib**: A selective VEGFR2 inhibitor; approved in China for gastric cancer.

#### 6.2.2 Resistance Mechanisms
Resistance to KDR-targeted therapies is a major clinical challenge. The primary resistance mechanisms include:

1. **Compensatory Upregulation of Alternative Angiogenic Pathways**: Tumors upregulate other pro-angiogenic factors (e.g., FGF2, PDGF-BB, Angiopoietin-2) to bypass KDR inhibition.
2. **KDR Kinase Domain Mutations**: Secondary mutations in the kinase domain (e.g., V1092I) can reduce drug binding affinity.
3. **Activation of Epithelial-Mesenchymal Transition (EMT)**: EMT-associated transcription factors (e.g., SNAIL, TWIST) downregulate KDR expression and promote invasion-independent growth.
4. **Pericyte Coverage**: Tumors recruit pericytes that provide survival signals to endothelial cells, reducing dependence on VEGF signaling.
5. **Alternative Receptor Activation**: Upregulation of other RTKs (e.g., FGFR1, EGFR) can activate shared downstream pathways (PI3K-AKT, RAS-ERK).

### 6.3 Pharmacogenomic Biomarkers

The *KDR* rs2071559 (C>T) polymorphism in the promoter region has been investigated as a predictive biomarker for anti-angiogenic therapy response. Patients carrying the T allele (reduced KDR expression) show improved progression-free survival when treated with sunitinib for renal cell carcinoma. However, the effect size is modest, and this biomarker has not yet been incorporated into routine clinical practice.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides comprehensive database accessions and bioinformatic resources for KDR:

| **Database** | **Accession/ID** | **URL** |
|:---|:---|:---|
| **NCBI Gene** | 3791 | https://www.ncbi.nlm.nih.gov/gene/3791 |
| **Ensembl** | ENSG00000128052 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000128052 |
| **UniProt** | P35968 | https://www.uniprot.org/uniprotkb/P35968/entry |
| **RCSB PDB** | 3V2A, 1VR2, 2X1W | https://www.rcsb.org/search?q=KDR |
| **HGNC** | 6307 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6307 |
| **OMIM** | 191306 | https://www.omim.org/entry/191306 |
| **ClinVar** | Gene: KDR | https://www.ncbi.nlm.nih.gov/clinvar/?term=KDR%5Bgene%5D |
| **COSMIC** | KDR | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=KDR |
| **STRING** | P35968 | https://string-db.org/network/P35968 |
| **BioGRID** | 112048 | https://thebiogrid.org/112048 |
| **PhosphoSitePlus** | KDR | https://www.phosphosite.org/proteinAction.action?id=1248 |
| **GTEx** | KDR | https://gtexportal.org/home/gene/KDR |
| **Human Protein Atlas** | ENSG00000128052 | https://www.proteinatlas.org/ENSG00000128052-KDR |

### Gene Ontology (GO) Terms

| **Ontology** | **Term** | **GO ID** |
|:---|:---|:---|
| **Molecular Function** | Vascular endothelial growth factor receptor activity | GO:0005021 |
| **Molecular Function** | Protein tyrosine kinase activity | GO:0004713 |
| **Molecular Function** | ATP binding | GO:0005524 |
| **Biological Process** | Angiogenesis | GO:0001525 |
| **Biological Process** | Vasculogenesis | GO:0001570 |
| **Biological Process** | Endothelial cell proliferation | GO:0001935 |
| **Biological Process** | Vascular endothelial growth factor signaling pathway | GO:0038084 |
| **Cellular Component** | Plasma membrane | GO:0005886 |
| **Cellular Component** | Receptor complex | GO:0043235 |
| **Cellular Component** | Caveola | GO:0005901 |

---

## Related Clinical & Scientific Guides

* [PMCH Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/pmch-gene-structure-function-pathway)
* [CYLC1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/cylc1-gene-structure-function-pathway)
* [CRX Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/crx-gene-structure-function-pathway)


## References

1. Shibuya, M. (2011). Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies. *Genes & Cancer*, 2(12), 1097–1105. https://doi.org/10.1177/1947601911423031

2. Holmes, K., Roberts, O. L., Thomas, A. M., & Cross, M. J. (2007). Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. *Cellular Signalling*, 19(10), 2003–2012. https://doi.org/10.1016/j.cellsig.2007.05.013

3. Koch, S., Tugues, S., Li, X., Gualandi, L., & Claesson-Welsh, L. (2011). Signal transduction by vascular endothelial growth factor receptors. *Biochemical Journal*, 437(2), 169–183. https://doi.org/10.1042/BJ20110301

4. Olsson, A. K., Dimberg, A., Kreuger, J., & Claesson-Welsh, L. (2006). VEGF receptor signalling - in control of vascular function. *Nature Reviews Molecular Cell Biology*, 7(5), 359–371. https://doi.org/10.1038/nrm1911

5. Ferrara, N., Gerber, H. P., & LeCouter, J. (2003). The biology of VEGF and its receptors. *Nature Medicine*, 9(6), 669–676. https://doi.org/10.1038/nm0603-669

6. Antonescu, C. R., Yoshida, A., Guo, T., Chang, N. E., Zhang, L., Agulnik, M., Qin, L. X., Brennan, M. F., & Singer, S. (2009). KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. *Cancer Research*, 69(18), 7175–7179. https://doi.org/10.1158/0008-5472.CAN-09-2068

7. Walter, J. W., North, P. E., Waner, M., Mizeracki, A., Blei, F., Walker, J. W., Reinisch, J. F., & Marchuk, D. A. (2002). Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma. *Genes, Chromosomes and Cancer*, 33(3), 295–303. https://doi.org/10.1002/gcc.10028

8. Karkkainen, M. J., Ferrell, R. E., Lawrence, E. C., Kimak, M. A., Levinson, K. L., McTigue, M. A., Alitalo, K., & Finegold, D. N. (2000). Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. *Nature Genetics*, 25(2), 153–159. https://doi